Antiviral antibacterial inorganic interior wall coating and preparation method thereof

Abstract

The application provides an antiviral and antibacterial inorganic interior wall coating, which comprises, in terms of mass fraction, 20-40 parts of silica sol and 0.8-1.5 parts of an antiviral and antibacterial preservative. The antiviral and antibacterial preservative comprises triazole compounds, isothiazolinone compounds, pyridine oxide sulfide compounds and chlorohydroxy diphenyl ether compounds, which can play a synergistic role, so that the coating has excellent antiviral and antibacterial activity, durability and alkali resistance. The silica sol and the antiviral and antibacterial preservative are reasonably compounded, so that the antiviral and antibacterial preservative fully plays its performance advantages, and the coating has good uniformity and stability.

Description

Technical Field

[0001] This invention belongs to the field of coating technology, specifically relating to an antiviral and antibacterial inorganic interior wall coating and its preparation method. Background Technology

[0002] Various viruses and bacteria exist in the environment, especially in crowded places such as hospitals and shopping malls, where the concentration of viruses and bacteria is higher. People are more susceptible to bacterial or viral infections upon contact with contaminated surfaces, particularly vulnerable groups with weakened immune systems. Furthermore, with increasing awareness of health and protection, the demand for antiviral and antibacterial coatings in homes, hospitals, and shopping malls is growing. However, existing antiviral or antibacterial coatings generally have limited antiviral or antibacterial properties, and these properties decline significantly after a period of use. Therefore, providing a coating with superior antiviral and antibacterial properties that can maintain their activity for a long time is of great significance in reducing the risk of daily bacterial or viral infections. Summary of the Invention

[0003] The purpose of this invention is to provide an antiviral and antibacterial inorganic interior wall coating and its preparation method. This coating has excellent antiviral and antibacterial activity, durability and alkali resistance.

[0004] According to one aspect of the present invention, an antiviral and antibacterial inorganic interior wall coating is provided, comprising, by weight, 20-40 parts of silica sol and 0.8-1.5 parts of an antiviral, bactericidal, and preservative agent; the antiviral, bactericidal, and preservative agent comprises a composite component, which includes triazole compounds, isothiazolinone compounds, thiopyridine compounds, and chlorohydroxydiphenyl ether compounds.

[0005] This invention introduces specific antiviral, bactericidal, and preservative agents into the coating formulation. The triazole compounds, isothiazolinone compounds, thiopyridine compounds, and chlorohydroxydiphenyl ether compounds in these agents work synergistically. On one hand, they exhibit a strong inactivation effect against influenza A virus, enterovirus, poliovirus, and stubborn viruses that survive on surfaces for weeks. On the other hand, they can solve the problem of mold on walls, killing mold spores, inhibiting their growth, and effectively repairing moldy walls. This gives the coating a powerful antiviral and antibacterial function. This invention solves the problem of poor antiviral and antibacterial activity and durability of coatings in existing technologies. On the other hand, it can effectively improve the coating's resistance to strong alkalis. Moreover, the antiviral, bactericidal, and preservative agent has good compatibility and compatibility with other components, which can effectively ensure the stability of the coating. In addition, by rationally compounding silica sol with the above-mentioned antiviral, bactericidal, and preservative agent, it is beneficial to promote the uniform dispersion of the antiviral, bactericidal, and preservative agent in the coating, giving the coating good uniformity and stability, and avoiding the problem of insufficient performance of antiviral, bactericidal, and preservative agents or coating deterioration caused by incompatibility of components in the coating.

[0006] Preferably, the mass ratio of triazole compounds, isothiazolinone compounds, thiopyridine compounds, and chlorohydroxydiphenyl ether compounds is 1:(2-3):(1-2):(1-2). The composite component prepared according to the above ratio has superior antiviral and antibacterial activity, durability, and alkali resistance.

[0007] Preferably, the triazole compounds include at least one of tebuconazole and tebuconazole; the isothiazolinone compounds include 1,2-benzisothiazolin-3-one; the thiopyridine oxide compounds include 2,2'-dithiodi(pyridine-1-oxide); and the chlorohydroxydiphenyl ether compounds include trichlorohydroxydiphenyl ether. The aforementioned specific triazole compounds, isothiazolinone compounds, thiopyridine oxide compounds, and chlorohydroxydiphenyl ether compounds can synergistically enhance the antiviral and antibacterial activity, antiviral and antibacterial durability, and resistance to strong alkalis of the coating.

[0008] Preferably, the antiviral, bactericidal, and preservative agent comprises a core and a capsule wall encapsulating the core. The core comprises a composite component, and the capsule wall comprises sodium alginate and modified starch. The modified starch is prepared by the following steps: gelatinizing the starch, then adding a composite amylase to the gelatinized starch for enzymatic hydrolysis and enzyme inactivation treatment, thereby obtaining the modified starch. The composite amylase comprises α-amylase, γ-amylase, and isoamylase. The pH of the enzymatic hydrolysis treatment is 6.5–7.5, and the temperature is 50–60°C. The modified starch prepared by the above method can synergistically combine with sodium alginate, giving the capsule wall good tensile strength and flexibility, which is beneficial for effectively encapsulating the core and further enhancing the long-lasting antiviral and antibacterial effect of the antiviral, bactericidal, and preservative agent. Simultaneously, it is beneficial for further optimizing the washability of the coating.

[0009] Preferably, in the composite amylase, the mass ratio of α-amylase, γ-amylase, and isoamylase is 1:(3-5):(1-3). By rationally setting the feeding ratio of α-amylase, γ-amylase, and isoamylase in the composite amylase, it is beneficial to improve the encapsulation ability of the capsule wall, thereby further optimizing the antiviral and antibacterial durability and washability of the coating.

[0010] Preferably, the silica sol is a zirconium-modified silica sol. The preparation method of the zirconium-modified silica sol includes the following steps: mixing silica sol with zirconium salt at 80-90°C and reacting the mixture. After the reaction is complete, a zirconium-modified silica sol is obtained. The zirconium salt includes at least one of zirconium acetylacetonate and zirconium isooctanoate. The above-mentioned organic zirconium salt can form stable chemical bonds with the silicon-oxygen bonds in the silica sol, giving the zirconium-modified silica sol good scrub resistance. Moreover, the tetravalent zirconium ions on the surface of the zirconium-modified silica sol can destroy the structure and function of bacteria, inhibiting bacterial growth and giving the zirconium-modified silica sol excellent antiviral and antibacterial activity.

[0011] Preferably, the mass ratio of zirconium salt to SiO2 contained in silica sol is (0.05-0.5):1.

[0012] Preferably, the antiviral and antibacterial inorganic interior wall coating further includes 12-30 parts water, 10-18 parts titanium dioxide, 10-25 parts filler, 8-16 parts toughening powder, 0.2-0.7 parts cellulose, 0.3-0.7 parts stabilizer, 0.2-0.6 parts dispersant, 0.1-0.5 parts defoamer, and 1-5 parts formaldehyde removal agent.

[0013] Preferably, the toughening powder includes Lotus Leaf Chemical SR-637. The main active ingredient of Lotus Leaf Chemical SR-637 is modified composite silicate powder, which can form a dense oxide layer at high temperatures, passivate the substrate surface, prevent open flame combustion, and improve the fire resistance of the coating. On the other hand, this toughening powder has good compatibility with the aforementioned silica sol, antiviral bactericide, and formaldehyde remover, which can further improve the stability of the coating.

[0014] Preferably, the stabilizer includes a quaternary ammonium salt. Since the toughening powder is prone to sedimentation, introducing a stabilizing quaternary ammonium salt into the coating can increase the coating's viscosity, allowing the solid particles to be more stably dispersed within the coating and preventing sedimentation, stratification, and other phenomena.

[0015] Preferably, the stabilizer is selected from lotus leaf WJ-100 or Aorun AR-CS1.

[0016] According to another aspect of the present invention, a method for preparing the above-mentioned antiviral and antibacterial inorganic interior wall coating is provided, comprising the following steps: dispersing cellulose in water, and then sequentially adding a dispersant, a stabilizer, a defoamer, a portion of silica sol, titanium dioxide, a filler, and a toughening powder; subsequently adding the remaining silica sol and mixing, and then sequentially adding a defoamer, a formaldehyde removal agent, and an antiviral, bactericidal, and preservative agent to obtain the antiviral and antibacterial inorganic interior wall coating.

[0017] Preferably, the cellulose comprises hydroxyethyl cellulose, selected from Ashland 250HBR.

[0018] Preferably, the titanium dioxide includes rutile titanium dioxide.

[0019] Preferably, the filler comprises calcined kaolin and 700-mesh calcium carbonate, wherein Ca... + Mg 2+ The content of calcium and magnesium ions is ≤0.01%. By controlling the content of calcium and magnesium ions to ≤0.01%, the reaction between the filler and potassium silicate in the toughening powder to form particles is effectively avoided.

[0020] Preferably, the thickener comprises an acrylate-modified copolymer selected from lotus leaf SR-800 or lotus leaf SR-801.

[0021] Preferably, the dispersant comprises a sodium salt selected from at least one of BASF CX4320, Nopco 5040, and Dow Quick-Dispersant.

[0022] Preferably, the defoamer includes an inorganic silicone defoamer. Detailed Implementation

[0023] To enable those skilled in the art to better understand the technical solutions of this invention, the technical solutions of this invention will be clearly and completely described below in conjunction with the embodiments of this invention. Obviously, the described embodiments are only some embodiments of this invention, and not all embodiments. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort should fall within the scope of protection of this invention.

[0024] Example 1

[0025] This embodiment provides an antiviral and antibacterial inorganic interior wall coating, the preparation method of which includes the following steps:

[0026] Step 1: Add hydroxyethyl cellulose to water, adjust the speed to 500 rpm / min, and disperse for 5 minutes until the hydroxyethyl cellulose is completely swollen and there are no obvious particles. Then, add the dispersant, stabilizer Lotus Leaf WJ-100 (the main active ingredient of Lotus Leaf WJ-100 is quaternary ammonium salt), and part of the defoamer in sequence, stir for 5 minutes, then add 1 / 2 of the silica sol and disperse evenly. Then, adjust the speed to 1200 rpm / min and add titanium dioxide, filler calcium carbonate, and toughening powder Lotus Leaf Chemical SR-637 in sequence (the main active ingredient of Lotus Leaf SR-637 is modified composite silicate powder). Then, adjust the speed to 1500 rpm / min and disperse at high speed for 20 minutes. Take a sample and measure the fineness with a scraper. The fineness should be less than or equal to 50 μm.

[0027] Step 2: After the fineness test is qualified, adjust the speed to 500 rpm / min, slowly add the thickener based on the step 1, stir for 3-5 minutes, then add the remaining amount of silica sol, stir for 5 minutes, then add the remaining defoamer, formaldehyde removal agent, and antiviral bactericidal preservative in sequence, and stir for 5 minutes. This yields the antiviral and antibacterial inorganic interior wall coating.

[0028] The aforementioned antiviral, bactericidal, and preservative agents include the capsule core and the capsule wall that encapsulates the capsule core;

[0029] The core is a composite component, which includes triazole compounds (tebuconazole), isothiazolinone compounds (1,2-benzisothiazolin-3-one), thiopyridine oxide compounds (2,2'-dithiobis(pyridine-1-oxide)), and chlorohydroxydiphenyl ether compounds (trichlorohydroxydiphenyl ether), and the mass ratio of triazole compounds, isothiazolinone compounds, thiopyridine oxide compounds, and chlorohydroxydiphenyl ether compounds is 1:2:1:1.

[0030] The capsule wall consists of sodium alginate and modified starch. The modified starch is prepared as follows: starch is dispersed in water, heated to 80℃ for gelatinization treatment for 10 min, then cooled to 60℃ and the pH value is adjusted to 6.5. A compound amylase (compound amylase is composed of α-amylase, isoamylase and γ-amylase in a mass ratio of 1:4:2) is added for enzymatic hydrolysis treatment for 4 h. After the enzymatic hydrolysis treatment is completed, the enzyme is inactivated for 30 min. After the enzyme inactivation treatment is completed, the mixture is cooled to room temperature and centrifuged. The precipitate after centrifugation is collected and dried to obtain modified starch.

[0031] The aforementioned silica sol is a zirconium-modified silica sol. The preparation method of the zirconium-modified silica sol is as follows: Zirconium isooctanoate is dissolved in a solvent to obtain a zirconium salt solution; the silica sol and the zirconium salt solution are mixed and reacted at 85°C according to a mass ratio of zirconium salt to SiO2 of 0.1:1. After the reaction is completed, the zirconium-modified silica sol is obtained.

[0032] Table 1. Formulation of the coating in this embodiment

[0033] water 23.18 silica sol 30 Titanium Dioxide 13 filler 18 toughening powder 10 Cellulose 0.62 Defoamer 0.5 dispersant 0.6 wetting agent 0.2 stabilizer 0.3 Thickener 0.1 Formaldehyde removal additives 2.5 Antiviral, bactericidal, and preservative 1

[0034] Example 2

[0035] This embodiment refers to Example 1 for preparing antiviral and antibacterial inorganic interior wall coatings. The difference between this embodiment and Example 1 is that the mass ratio of triazole compounds, isothiazolinone compounds, thiopyridine compounds, and chlorohydroxydiphenyl ether compounds in the antiviral, bactericidal, and preservative agents used in this embodiment is 1:2:1:3. Apart from the above difference, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0036] Example 3

[0037] This embodiment refers to Example 1 for preparing antiviral and antibacterial inorganic interior wall coatings. The difference between this embodiment and Example 1 is that the mass ratio of triazole compounds, isothiazolinone compounds, thiopyridine compounds, and chlorohydroxydiphenyl ether compounds in the antiviral, bactericidal, and preservative agents used in this embodiment is 1:2:1:0.3. Apart from the above difference, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0038] Example 4

[0039] This embodiment refers to Example 1 for preparing antiviral and antibacterial inorganic interior wall coating. The difference between this embodiment and Example 1 is that in the preparation of the antiviral, bactericidal, and preservative agent, propiconazole of the same mass is used instead of tebuconazole in Example 1 as the triazole compound in this embodiment. Apart from the above differences, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0040] Example 5

[0041] This embodiment refers to Example 1 for preparing antiviral and antibacterial inorganic interior wall coatings. The difference between this embodiment and Example 1 is that in the preparation of the antiviral, bactericidal, and preservative agent, the same mass of 5-chloro-2-methyl-4-isothiazolin-3-one is used instead of 1,2-benzisisothiazolin-3-one in Example 1 as the isothiazolinone compound in this embodiment. Apart from the above differences, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0042] Example 6

[0043] This embodiment refers to Example 1 for preparing an antiviral and antibacterial inorganic interior wall coating. The difference between this embodiment and Example 1 is that the capsule wall of the antiviral, bactericidal, and preservative agent in this embodiment consists only of sodium alginate. Apart from the above differences, the materials and processes used in this embodiment are strictly consistent with those in Example 1.

[0044] Example 7

[0045] This embodiment refers to Example 1 for preparing antiviral and antibacterial inorganic interior wall coatings. The difference between this embodiment and Example 1 is that the composite amylase used in the preparation of modified starch in this embodiment only includes α-amylase and γ-amylase. Apart from the above differences, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0046] Example 8

[0047] This embodiment refers to Example 1 for preparing antiviral and antibacterial inorganic interior wall coatings. The difference between this embodiment and Example 1 is that the composite amylase used in the preparation of modified starch in this embodiment only includes α-amylase and isoamylase. Apart from the above differences, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0048] Example 9

[0049] This embodiment refers to Example 1 for preparing antiviral and antibacterial inorganic interior wall coating. The difference between this embodiment and Example 1 is that in the preparation of modified starch, the mass ratio of α-amylase, isoamylase, and γ-amylase in the composite amylase used in this embodiment is 1:3:5. Apart from the above difference, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0050] Example 10

[0051] This embodiment refers to Example 1 for preparing antiviral and antibacterial inorganic interior wall coating. The difference between this embodiment and Example 1 is that in the preparation of modified starch, the mass ratio of α-amylase, isoamylase, and γ-amylase in the composite amylase used in this embodiment is 1:1:1. Apart from the above difference, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0052] Example 11

[0053] This embodiment refers to Example 1 for preparing an antiviral and antibacterial inorganic interior wall coating. The difference between this embodiment and Example 1 is that in the preparation of the silica sol, the same mass of aluminum-modified silica sol is used instead of the zirconium-modified silica sol in Example 1. Apart from the above differences, the materials and processes used in this embodiment are strictly consistent with those in Example 1.

[0054] Example 12

[0055] This embodiment refers to Example 1 for preparing an antiviral and antibacterial inorganic interior wall coating. The difference between this embodiment and Example 1 is that in the preparation of the silica sol, the same mass of inorganic zirconium salt ZrOCl2·8H2O is used instead of the organic zirconium salt zirconium isooctanoate in Example 1. Apart from the above differences, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0056] Comparative Example 1

[0057] This comparative example prepares an antiviral and antibacterial inorganic interior wall coating according to Example 1. The difference between this comparative example and Example 1 is that the composite components used in the preparation of the antiviral, bactericidal, and preservative agent in this comparative example only include triazole compounds, isothiazolinone compounds, and thiopyridine compounds. Apart from the above differences, the materials and process operations used in this comparative example are strictly consistent with those in Example 1.

[0058] Comparative Example 2

[0059] This comparative example prepares an antiviral and antibacterial inorganic interior wall coating according to Example 1. The difference between this comparative example and Example 1 is that the composite components used in the preparation of the antiviral, bactericidal, and preservative agent in this comparative example only include triazole compounds, isothiazolinone compounds, and chlorohydroxydiphenyl ether compounds. Apart from the above differences, the materials and process operations used in this comparative example are strictly consistent with those in Example 1.

[0060] Comparative Example 3

[0061] This comparative example prepares an antiviral and antibacterial inorganic interior wall coating according to Example 1. The difference between this comparative example and Example 1 is that the amount of zirconium-modified silica sol used in Example 1 is adjusted to 5 parts during the preparation of the antiviral and antibacterial inorganic interior wall coating. Apart from the above differences, the materials and processes used in this comparative example are strictly consistent with those in Example 1.

[0062] Comparative Example 4

[0063] This comparative example prepares an antiviral and antibacterial inorganic interior wall coating according to Example 1. The difference between this comparative example and Example 1 is that in the preparation of the antiviral and antibacterial inorganic interior wall coating in this comparative example, the same mass of SiO2 aerogel is used instead of the zirconium-modified silica sol in Example 1. Apart from the above differences, the materials and process operations used in this comparative example are strictly consistent with those in Example 1.

[0064] Comparative Example 5

[0065] This comparative example prepares an antiviral and antibacterial inorganic interior wall coating according to Example 1. The difference between this comparative example and Example 1 is that in the preparation of the antiviral, bactericidal, and preservative agent, the same mass of tebuconazole is used instead of the composite component in Example 1 as the core of this comparative example. Apart from the above differences, the materials and processes used in this comparative example are strictly consistent with those in Example 1.

[0066] Comparative Example 6

[0067] This comparative example prepares an antiviral and antibacterial inorganic interior wall coating according to Example 1. The difference between this comparative example and Example 1 is that in the preparation of the antiviral, bactericidal, and preservative agent, the same mass of 1,2-benzisothiazolin-3-one is used instead of the composite component in Example 1 as the core of this comparative example. Apart from the above differences, the materials and processes used in this comparative example are strictly consistent with those in Example 1.

[0068] Test Example 1

[0069] 1. Test subject:

[0070] The antiviral and antibacterial inorganic interior wall coatings prepared in Examples 1-12 and Comparative Examples 1-6 were used as the test objects in this test example.

[0071] 2. Testing Method:

[0072] (1) Antiviral and antifungal properties: The antiviral rate and antifungal grade of the coating were tested in accordance with T / CNCIA01014-2020 "Antibacterial and Antiviral Coatings".

[0073] (2) Scrub resistance and alkali resistance: The scrub resistance and alkali resistance of the coating were tested in accordance with GB / T9756 2018 Synthetic Resin Emulsion Interior Wall Coatings.

[0074] 3. Test Results

[0075] Table 2. Performance test results of the coatings in Examples 1-12 and Comparative Examples 1-6.

[0076]

[0077] The test results are shown in Table 2. Comparing the performance test results of Example 1 with those of Comparative Examples 1-2 and 5-6, it can be found that the antiviral and antibacterial activity, durability, and alkali resistance of the coatings prepared in Comparative Examples 1-2 and 5-6 are lower than those in Example 1. The reason is that, under the same conditions of other materials and operations in the preparation of the coatings, the antiviral, bactericidal, and preservative agents used in Comparative Examples 1-2 and 5-6 do not simultaneously include triazole compounds, isothiazolinone compounds, thiopyridine compounds, and chlorohydroxydiphenyl ether compounds. The components are therefore unable to exert a synergistic effect, resulting in poorer antiviral and antibacterial activity, durability, and alkali resistance of the coatings.

[0078] Comparing the performance test results of Example 1 with those of Comparative Examples 3-4, it can be found that the antiviral and antibacterial activity, durability, and alkali resistance of the coatings prepared in Comparative Examples 3-4 are lower than those of Example 1. This is because, under the same conditions of other materials and operations in preparing the coatings, the content of silica sol in Comparative Example 3 was too low, and silica sol was not used in the preparation of the coating in Comparative Example 4. This resulted in poor compatibility of the components in the coatings, thus deteriorating the antiviral and antibacterial activity, durability, and alkali resistance of the coatings.

[0079] The performance test results of Example 1 were compared with those of Examples 2-5. Table 2 shows that, under the same conditions of other materials and operations used in preparing the coating, the mass ratio of triazole compounds, isothiazolinone compounds, thiopyridine compounds, and chlorohydroxydiphenyl ether compounds in Examples 2 and 3 did not meet the requirement of 1:(2-3):(1-2):(1-2). In Example 4, propiconazole was used as a triazole compound to prepare an antiviral, bactericidal, and preservative agent, and in Example 5, 5-chloro-2-methyl-4-isothiazolin-3-one was used as an isothiazolinone compound to prepare an antiviral, bactericidal, and preservative agent. Therefore, the antiviral and antibacterial activity, durability, and alkali resistance of the coatings obtained in these examples were lower than those in Example 1. This demonstrates that, compared to Examples 2-3, Example 1, by rationally setting the ratio of triazole compounds, isothiazolinone compounds, thiopyridine compounds, and chlorohydroxydiphenyl ether compounds, improves the antiviral and antibacterial activity, durability, and alkali resistance of the coating. Compared to Examples 4-5, the specific triazole compounds, isothiazolinone compounds, thiopyridine compounds, and chlorohydroxydiphenyl ether compounds in Example 1 can work together to further improve the antiviral and antibacterial activity, durability, and alkali resistance of the coating.

[0080] The performance test results of Examples 1 and 6-10 were compared. Table 2 shows that, under the same conditions of other materials and operations in preparing the coatings, the capsule wall of the antiviral, bactericidal, and preservative agent in Example 6 only included sodium alginate. Examples 7 and 8 used only α-amylase and γ-amylase, and α-amylase and isoamylase as composite amylases to prepare modified starch, respectively. In Examples 9 and 10, the mass ratio of α-amylase, isoamylase, and γ-amylase in the composite amylases did not meet the requirement of 1:(3-5):(1-3). Therefore, the antiviral, antibacterial durability, and washability of the resulting coatings were lower than those of Example 1. This indicates that, compared to Examples 6-10, Example 1, by using a specific composite amylase to prepare modified starch, allows the modified starch and sodium alginate to work synergistically, giving the capsule wall good tensile strength and flexibility, effectively embedding the capsule core, thus resulting in better long-lasting antiviral, antibacterial, and washability of the antiviral, bactericidal, and preservative agent.

[0081] The performance test results of Example 1 were compared with those of Examples 11-12. Table 2 shows that, under the same conditions of other materials and operations in preparing the coating, Example 11 used aluminum-modified silica sol as the silica sol, while Example 12 used inorganic zirconium salt to prepare zirconium-modified silica sol. The resulting coatings exhibited lower scrub resistance than those of Example 1. This indicates that, compared to Examples 11-12, Example 1, by using organic zirconium salt to prepare modified zirconium silica sol, allows the organic zirconium salt to form stable chemical bonds with the silicon-oxygen bonds in the silica sol, resulting in good scrub resistance. Furthermore, the tetravalent zirconium ions on the surface of the zirconium-modified silica sol can disrupt the structure and function of bacteria, inhibiting bacterial growth, thus improving the antibacterial effect, adhesion, scrub resistance, and stability of the coating.

[0082] The above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention, but such modifications or substitutions are all within the scope of protection of the present invention.

Claims

1. An antiviral and antibacterial inorganic interior wall coating, characterized in that, Based on the weight percentage, it includes 20-40 parts of silica sol and 0.8-1.5 parts of antiviral, bactericidal, and preservative agents; The antiviral, bactericidal, and preservative agent comprises a compound component, which includes triazole compounds, isothiazolinone compounds, thiopyridine compounds, and chlorohydroxydiphenyl ether compounds. The antiviral, bactericidal, and preservative agent includes a capsule core and a capsule wall that encapsulates the capsule core; The capsule core includes the composite components, and the capsule wall includes sodium alginate and modified starch. The method for preparing the modified starch includes the following steps: gelatinizing the starch, then adding a complex amylase to the gelatinized starch and sequentially performing enzymatic hydrolysis and enzyme inactivation treatments to obtain the modified starch; the complex amylase includes α-amylase, γ-amylase, and isoamylase; the pH of the enzymatic hydrolysis treatment is 6.5~7.5, and the temperature is 50~60℃; The silica sol is a zirconium-modified silica sol, and the preparation method of the zirconium-modified silica sol includes the following operations: The silica sol and zirconium salt are mixed and reacted at 80~90℃ to obtain the zirconium-modified silica sol after the reaction is completed; the zirconium salt includes at least one of zirconium acetylacetonate and zirconium isooctanoate.

2. The antiviral and antibacterial inorganic interior wall coating as described in claim 1, characterized in that, The mass ratio of the triazole compound, the isothiazolinone compound, the thiopyridine compound, and the chlorohydroxydiphenyl ether compound is 1:(2~3):(1~2):(1~2).

3. The antiviral and antibacterial inorganic interior wall coating as described in claim 1 or 2, characterized in that, The triazole compounds include at least one of tebuconazole and tebuconazole; The isothiazolinone compounds include 1,2-benzisothiazolin-3-one; The thiopyridine compounds include 2,2'-dithiobis(pyridine-1-oxide); The chlorohydroxydiphenyl ether compounds include trichlorohydroxydiphenyl ether.

4. The antiviral and antibacterial inorganic interior wall coating as described in claim 1, characterized in that, In the complex amylase, the mass ratio of the α-amylase, the γ-amylase, and the isoamylase is 1:(3~5):(1~3).

5. The antiviral and antibacterial inorganic interior wall coating as described in claim 1, characterized in that, The antiviral and antibacterial inorganic interior wall coating also includes 12-30 parts water, 10-18 parts titanium dioxide, 10-25 parts filler, 8-16 parts toughening powder, 0.2-0.7 parts cellulose, 0.3-0.7 parts stabilizer, 0.2-0.6 parts dispersant, 0.1-0.5 parts defoamer, and 1-5 parts formaldehyde removal agent.

6. The antiviral and antibacterial inorganic interior wall coating as described in claim 5, characterized in that, The toughening powder includes Lotus Leaf Chemical SR-637.

7. The antiviral and antibacterial inorganic interior wall coating as described in claim 6, characterized in that, The stabilizer includes quaternary ammonium salts.

8. A method for preparing the antiviral and antibacterial inorganic interior wall coating as described in any one of claims 1 to 7, characterized in that, The process includes the following steps: dispersing cellulose in water, then sequentially adding a dispersant, stabilizer, defoamer, a portion of silica sol, titanium dioxide, filler, and toughening powder; subsequently adding the remaining silica sol and mixing, followed by sequentially adding a defoamer, formaldehyde removal agent, and antiviral, bactericidal, and preservative agent, thereby obtaining the antiviral and antibacterial inorganic interior wall coating.

Images